Incyte Stock
Incyte Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- William J. Meury
- Employees
- 2,844
- Market cap
- $22.9 B
- IPO
- 04/11/1993
Incyte Corporation is a healthcare company in the biotechnology sector headquartered in Wilmington, US. Founded in 1991, the biopharmaceutical firm focuses on the research, development, and global marketing of its own innovative therapies. The current product offerings include JAKAFI for myelofibrosis and polycythemia…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Incyte stock: price history
1D
-0.2%
1W
+0.2%
1M
-9.4%
6M
+15.6%
YTD
+14.5%
1Y
+29.5%
2Y
+70.9%
5Y
+72.5%
10Y
+29.8%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~8% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Incyte stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Incyte Corporation is a biopharmaceutical company primarily focused on the research, development, and worldwide distribution of innovative therapeutics. The business model is based on the sale of patent-protected medications for treating cancer and hematological conditions such as myelofibrosis or leukemia. Core products include JAKAFI, PEMAZYRE, and ICLUSIG, with the company generating significant revenue not only from direct product sales but also from licensing fees and milestone payments. Incyte leverages strategic alliances with partners such as Novartis and Eli Lilly to research new combination therapies. The majority of revenues are generated in the United States, while the research pipeline is continuously expanded with new indications in the field of oncology.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Agenus Inc.Description
Eli Lilly and CompanyDescriptionAsk the agents about Incyte
Analyst assessment of Incyte
PRICE TARGET LOW
US$104.00
CONSENSUS
US$134.40
MEDIAN
US$130.00
PRICE TARGET HIGH
US$157.00
0
STRONG BUY
23
BUY
20
HOLD
1
SELL
0
STRONG SELL
44
TOTAL · Buy
As of: 14/10/2026
Incyte stock metrics
P/E
13.91
P/B
3.57
EV/EBITDA
9.18
RETURN ON EQUITY
9.2%
NET MARGIN
35.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.1%
FLOAT SHARES
200,844,732
AVG. DAILY VOLUME (30D)
1,687,108
Insider transactions (SEC)
Heeson Lee
BAKER BROS. ADVISORS LP
HARRIGAN EDMUND
Clancy Paul J
BAKER BROS. ADVISORS LP
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Incyte stock
What does Incyte do?
Incyte Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is William J. Meury, the company employs around 2,844 people.
The IPO was on 04/11/1993; the stock trades on NASDAQ under the ticker INCY.
What do analysts say about Incyte stock?
44 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$134.40, ranging from US$104.00 to US$157.00, with a median of US$130.00.
This is an external assessment, not a statement by Market Jury.
When does Incyte report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly -8% stronger than usual.
Does Incyte pay a dividend?
No, Incyte currently does not pay a dividend.
Which stocks are comparable to Incyte?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Exelixis, Neurocrine Biosciences, Summit Therapeutics and Halozyme Therapeutics.
How can I get Incyte stock analyzed?
Clicking "Analyze stock" lets five strategies assess Incyte against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.